EUVIMEDEUVIMED entdecken
Crossref

Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time

Lachlan Yaksich, Gunter Hartel, Benedict J Panizza, David C Whiteman, Annika Antonsson

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Lachlan Yaksich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastics and Reconstructive Surgery, Greenslopes Private Hospital, Brisbane, Australia. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections, Human Papillomavirus Viruses, Papillomaviridae. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: MSD Australia, Merck Sharp and Dohme Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of human papillomavirus (HPV)‐positive oropharyngeal cancer (OPC) is increasing in Australia, yet very little is known about the dynamics of the HPV types in OPC over time. Here we used a database to identify oropharyngeal cancer patients diagnosed in Queensland in 2009–2011 and 2019–2021. We retrieved and extracted DNA from 526 formalin‐fixed paraffin‐embedded tumour tissues, which were tested for DNA quality and 14 high‐risk (HR)‐HPV types. The HPV prevalence in OPC tumour tissue increased from 45% in 2009–2011 to 68% in 2019–2021. HPV‐16 was the most common HPV type, found in 90% of all OPCs. HPV‐33 (5.7%) was the second most common HPV type followed by HPV‐35 (1.6%). Other HPV types found were HPV‐18 (1.4%), HPV‐39 (0.3%), HPV‐56 (0.6%) and HPV‐59 (0.6%). Males had a significantly higher HPV prevalence (68.1%) compared to females (35.9%; p < .0001). First Nation Australians had much lower HPV prevalence in their OPC tumours (25.0%) compared with non‐First Nation Australians (68.8%; p = .0005). Without an early detection program for OPC, primary prevention with vaccination remains the best available strategy for control, and our findings suggest that HPV vaccination will be able to reduce HPV‐driven OPC in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsPapillomavirus InfectionsHuman Papillomavirus VirusesPapillomaviridaeHumansFemaleMalePrevalenceMiddle AgedAgedAustraliaDNA, ViralQueenslandAdult

Stichwörter der Autor:innen

change over timehuman papillomavirusoropharyngeal cancerrisk factorsvaccine prevention

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Department of Plastics and Reconstructive Surgery, Greenslopes Private Hospital, Brisbane, Australia.
  • The Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Griffith Institute for Biomedicine and Glycomics, Griffith University, Queensland, Australia.
  • Department of Otolaryngology-Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia.
  • Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Förderung

  • MSD Australia
  • Merck Sharp and Dohme Australia

Zitieren

APA

Yaksich, L., Hartel, G., Panizza, B. J., Whiteman, D. C., & Antonsson, A. (2026). Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time. International Journal of Cancer. https://doi.org/10.1002/ijc.70432

Vancouver

Yaksich L, Hartel G, Panizza BJ, Whiteman DC, Antonsson A. Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time. International Journal of Cancer. 2026. doi:10.1002/ijc.70432

BibTeX
@article{Yaksich2026,
  author = {Yaksich, Lachlan and Hartel, Gunter and Panizza, Benedict J and Whiteman, David C and Antonsson, Annika},
  title = {Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70432}
}
Kostenlos starten →